Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Reshma Kewalramani sold 241 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $165.41, for a total transaction of $39,863.81. Following the sale, the chief marketing officer now owns 13,736 shares in the company, valued at approximately $2,272,071.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Reshma Kewalramani also recently made the following trade(s):

  • On Tuesday, February 19th, Reshma Kewalramani sold 1,488 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $186.94, for a total transaction of $278,166.72.

Vertex Pharmaceuticals stock traded down $1.50 during trading hours on Friday, hitting $168.73. The company had a trading volume of 896,463 shares, compared to its average volume of 1,079,231. The firm has a market cap of $43.60 billion, a PE ratio of 52.70, a P/E/G ratio of 2.47 and a beta of 1.56. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $144.07 and a fifty-two week high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.49. The firm had revenue of $857.00 million for the quarter, compared to analyst estimates of $853.00 million. Vertex Pharmaceuticals had a net margin of 66.01% and a return on equity of 22.63%. The company’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.76 EPS. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 3.06 EPS for the current fiscal year.

A number of research firms have recently issued reports on VRTX. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 26th. ValuEngine upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. BMO Capital Markets boosted their price target on shares of Vertex Pharmaceuticals to $234.00 and gave the company an “outperform” rating in a report on Wednesday, February 6th. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $209.00 price target on shares of Vertex Pharmaceuticals in a report on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $203.35.

A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its position in Vertex Pharmaceuticals by 19.3% in the first quarter. FMR LLC now owns 24,434,159 shares of the pharmaceutical company’s stock worth $4,494,663,000 after acquiring an additional 3,951,050 shares in the last quarter. BlackRock Inc. grew its position in Vertex Pharmaceuticals by 2.9% in the first quarter. BlackRock Inc. now owns 20,176,298 shares of the pharmaceutical company’s stock worth $3,711,428,000 after acquiring an additional 568,488 shares in the last quarter. Vanguard Group Inc grew its position in Vertex Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc now owns 18,775,252 shares of the pharmaceutical company’s stock worth $3,618,743,000 after acquiring an additional 213,550 shares in the last quarter. Wellington Management Group LLP grew its position in Vertex Pharmaceuticals by 2.4% in the first quarter. Wellington Management Group LLP now owns 8,828,785 shares of the pharmaceutical company’s stock worth $1,624,056,000 after acquiring an additional 210,383 shares in the last quarter. Finally, Jennison Associates LLC grew its position in Vertex Pharmaceuticals by 11.9% in the fourth quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock worth $1,150,296,000 after acquiring an additional 739,128 shares in the last quarter. Hedge funds and other institutional investors own 94.92% of the company’s stock.

WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells $39,863.81 in Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-cmo-sells-39863-81-in-stock/3015089.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

See Also: Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.